Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie av medisinen kalt abrokitinib hos barn 6 til mindre enn 12 år med moderat til alvorlig eksem

10. november 2026 oppdatert av: Pfizer

En 16 uker

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Detaljert beskrivelse

Different questionnaires will be used to find out how the participant's eczema is doing during the research study. An electronic diary, which looks like a cellular phone, will be used to collect the questionnaire information and other research study-related information. It will also be used to remind participants to take the test medicine each day and to fill out the questionnaires. Participants will also be asked to wear something on their wrist that looks like a children's wristwatch so we can know when they are scratching their skin because of their atopic dermatitis. Laboratory tests, physical examinations and vital signs (height, weight, temperature, blood pressure and heart rate) will be conducted before and during the research study to monitor your child's health. Participants will need to come to the clinic for research study visits and at other times during the research study, the research study doctor or nurse will call the participants to find out the participant is doing.

Studietype

Intervensjonell

Registrering (Faktiske)

151

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35244
        • Cahaba Dermatology & Skin Health Center, LLC
    • Arkansas
      • North Little Rock, Arkansas, Forente stater, 72117
        • Arkansas Research Trials
    • California
      • San Diego, California, Forente stater, 92123
        • Investigational Drug Service - Rady Childrens Hospital-San Diego
      • San Diego, California, Forente stater, 92123
        • University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm
    • Florida
      • Jacksonville, Florida, Forente stater, 32256
        • Solutions Through Advanced Research
    • Idaho
      • Meridian, Idaho, Forente stater, 83646
        • Ada West Research
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46250
        • Dawes Fretzin Clinical Research Group, LLC
    • Missouri
      • St Louis, Missouri, Forente stater, 63104
        • Saint Louis University - Department of Dermatology
    • South Carolina
      • Charleston, South Carolina, Forente stater, 29425
        • Medical University of South Carolina - Department of Dermatology
      • Charleston, South Carolina, Forente stater, 29425
        • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
      • Charleston, South Carolina, Forente stater, 29425
        • Medical University of South Carolina - Walton Research Building
      • Greenville, South Carolina, Forente stater, 29607
        • Tribe Clinical Research, LLC
    • Texas
      • San Antonio, Texas, Forente stater, 78235
        • Texas Dermatology and Laser Specialists
      • Fukuoka, Japan, 811-1394
        • Fukuoka National Hospital
      • Fukuoka, Japan, 819-0042
        • Saruta Dermatology Clinic
    • Kanagawa
      • Yokohama, Kanagawa, Japan, 220-6208
        • Queen's square Medical Facilities Queen's square Dermatology and Allergology
    • Osaka
      • Sakai, Osaka, Japan, 593-8324
        • Dermatology and Ophthalmology Kume Clinic
    • Tokyo
      • Setagaya-ku, Tokyo, Japan, 157-0066
        • Sasamoto Children's Clinic
      • Shanghai, Kina, 200062
        • Shanghai Children's Hospital
      • Shanghai, Kina, 200092
        • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100045
        • Beijing Children's hospital, Capital Medical University
    • Guangdong
      • Shenzhen, Guangdong, Kina, 518026
        • Shenzhen Children's Hospital
    • Hunan
      • Changsha, Hunan, Kina, 410007
        • Hunan Children's Hospital
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330000
        • Dermatology Hospital of Jiangxi Province
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200040
        • Shanghai Children's Hospital
    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310009
        • Hangzhou Third People's Hospital
      • Chihuahua City, Mexico, 31238
        • Servicios Hospitalarios de México S.A. de C.V. (Hospital Angeles Chihuahua)
    • Mexico City
      • Mexico City, Mexico City, Mexico, 06720
        • Hospital Infantil de México Federico Gómez
    • Nuevo León
      • Monterrey, Nuevo León, Mexico, 64718
        • Eukarya Pharmasite S.C.
    • Veracruz
      • Veracruz, Veracruz, Mexico, 91900
        • Arke SMO S.A. de C.V.
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Polen, 30-002
        • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Polen, 20-573
        • LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Polen, 02-625
        • Centrum Medyczne Evimed
    • Silesian Voivodeship
      • Chorzów, Silesian Voivodeship, Polen, 41-500
        • DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
      • Katowice, Silesian Voivodeship, Polen, 40-611
        • Centrum Medyczne Angelius Provita
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Polen, 90-436
        • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    • Świętokrzyskie Voivodeship
      • Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Polen, 27-400
        • Dermedic Jacek Zdybski
      • Zaragoza, Spania, 50009
        • Hospital Universitario Miguel Servet
    • A Coruña [LA Coruña]
      • Santiago de Compostela, A Coruña [LA Coruña], Spania, 15706
        • CHUS - Hospital Clinico Universitario
    • Barcelona [barcelona]
      • Granollers, Barcelona [barcelona], Spania, 08402
        • Hospital General de Granollers
    • North Rhine-Westphalia
      • Münster, North Rhine-Westphalia, Tyskland, 48149
        • Universitätsklinikum Münster
    • Saxony
      • Dresden, Saxony, Tyskland, 01307
        • Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
      • Pécs, Ungarn, 7622
        • University of Pecs
    • Baranya
      • Pécs, Baranya, Ungarn, 7632
        • Pécsi Tudományegyetem Klinikai Központ
    • Bekes County
      • Békéscsaba, Bekes County, Ungarn, 5600
        • Trial Pharma Kft.
    • Csongrád-csanád
      • Szeged, Csongrád-csanád, Ungarn, 6720
        • Szegedi Tudományegyetem Bőrgyógyászati és Allergológiai Klinika
    • Pest County
      • Budapest, Pest County, Ungarn, 1033
        • Clinexpert Kft.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 år til 11 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria Children aged 6 to <12 years at the time of informed consent/assent.

• No contraception methods are required for male participants. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.

Disease Characteristics:

Participants who meet all of the following AD criteria:

  • A documented diagnosis of chronic AD for at least 1 year prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria[19]; and
  • A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
  • Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy

Other Inclusion Criteria:

Body weight ≥15 kg

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions:

Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

Have any of the following medical conditions:

  • Infections:

    • Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (Baseline) or have superficial skin infections within 1 week of Day 1.
    • History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
    • Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
    • Infection with HIV, hepatitis B, and/or hepatitis C
    • Evidence of active TB or inadequately treated latent TB.
  • Skin Conditions:

    - Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.

  • Other Conditions:

    • Documented history of skeletal dysplasia.
    • Documented history of retinal detachment.
    • History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
    • Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
    • Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
    • Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.

Prior/Concomitant Therapy:

Prior treatment with a systemic JAK inhibitor for AD. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.

Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes, strong inducers of CYP2C9 enzymes, P-gp substrates with narrow therapeutic index and sensitive CYP2C19 substrates is not allowed in the study.

Prior/Concurrent Clinical Study Experience:

Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Trippel

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Abrocitinib

Abrocitinib administered as liquid oral suspension.

Abrocitinib administered as liquid oral suspension.

Andre navn:
  • PF-04965842
Placebo komparator: Matching Placebo

Placebo administered as liquid oral suspension.

Placebo administered as liquid oral suspension.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at Week 12
Tidsramme: At week 12

The difference in proportion of responders based on vIGA at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12
Response based on achieving ≥75% improvement from baseline in the Eczema Area and Severity Index (EASI)-75 at Week 12
Tidsramme: At week 12

The difference in proportion of responders based on EASI-75 at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline (CFB) in the Worst Itch Numerical Rating Scale (WI-NRS) at Week 2
Tidsramme: At week 2

The difference in mean CFB in WI-NRS total score at Week 2 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 2
Response based on achieving at least a 4-point improvement from baseline in the WI-NRS at Week 12
Tidsramme: At week 12

The difference in proportion of responders based on achieving at least a 4-point improvement from baseline in the WI-NRS at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12
Response based on achieving WI-NRS <2 at Week 12
Tidsramme: At week 12

The difference in proportion of responders based on achieving WI-NRS <2 at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo

At week 12

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

24. juli 2025

Primær fullføring (Antatt)

2. mai 2027

Studiet fullført (Antatt)

2. mai 2027

Datoer for studieregistrering

Først innsendt

29. januar 2025

Først innsendt som oppfylte QC-kriteriene

29. januar 2025

Først lagt ut (Faktiske)

4. februar 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

10. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • B7451023
  • 2023-509121-51-00 (Registeridentifikator: CTIS (EU))
  • 2023 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere